Clinical Trials Directory

Trials / Sponsors / Eikon Therapeutics

Eikon Therapeutics

Industry · 10 registered clinical trials — 6 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With
Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
Phase 2 / Phase 32026-05-18
RecruitingEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer
Phase 1 / Phase 22026-01-20
RecruitingSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patient
Advanced Melanoma
Phase 2 / Phase 32025-05-22
RecruitingA Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Advanced Solid Tumors
Phase 1 / Phase 22025-04-30
RecruitingA Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NSCLC
Phase 22024-02-06
RecruitingA First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1 / Phase 22023-12-11
CompletedBDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Tumor, Solid
Phase 22021-08-30
CompletedClinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tu
Tumor, Solid
Phase 12021-06-22
CompletedBDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
Tumor, Solid
Phase 12019-11-21
CompletedBDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
Tumor, Solid
Phase 12018-02-15